Cocrystal Pharma Reports Financial Results and Updates on Antiviral Drug-Development ProgramsOn November 13, 2024, Cocrystal Pharma, Inc. (NASDAQ: COCP) provided an overview of its financial results for the third quarter of 2024 and delivered updates

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cocrystal Pharma’s 8K filing here.

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.

Further Reading